Scarica l'app Stockscreener
1.30
7.14%
-0.10
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World
Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.00 Average Price Target from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript - MSN
Skye Bioscience (NASDAQ:SKYE) Receives Outperform Rating from William Blair - MarketBeat
Skye Bioscience promotes Tu Diep to COO post - The Pharma Letter
Craig Hallum Issues Pessimistic Forecast for Skye Bioscience (NASDAQ:SKYE) Stock Price - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Announces Quarterly Earnings Results - MarketBeat
Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year - Investing.com Canada
Craig Hallum Cuts Skye Bioscience (NASDAQ:SKYE) Price Target to $14.00 - Defense World
Skye Bioscience’s (SKYE) “Outperform” Rating Reiterated at William Blair - Defense World
Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year By Investing.com - Investing.com South Africa
SKYE Stock Price and Chart — NASDAQ:SKYE - TradingView
Skye Bioscience’s Positive Earnings Call Highlights Nimacimab Progress - TipRanks
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Skye Bioscience (SKYE) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Citizens JMP reiterates Skye Bioscience at market outperform By Investing.com - Investing.com Canada
Citizens JMP reiterates Skye Bioscience at market outperform - Investing.com India
Skye Bioscience (NASDAQ:SKYE) Shares Down 31% – Time to Sell? - Defense World
Skye Bioscience (NASDAQ:SKYE) Stock Price Down 31% – Time to Sell? - Defense World
Skye Bioscience Reports 2024 Financial Results and Trial Progress - TipRanks
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period - MSN
Earnings call transcript: Skye Bioscience Q4 2024 highlights financials, product progress - Investing.com
Skye Bioscience Inc. (SKYE) reports earnings - Quartz
Skye Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Skye Bioscience Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Business Update - Marketscreener.com
Skye Bioscience, Inc. SEC 10-K Report - TradingView
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Skye's Obesity Drug Trial Hits Major Milestone with Strong Financial Backing - StockTitan
Skye Bioscience Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
SKYE BIOSCIENCE Earnings Preview: Recent $SKYE Insider Trading, Hedge Fund Activity, and More - Nasdaq
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025 - The Manila Times
Skye Bioscience to Host Conference Call on March 20, 2025, to Discuss Q4 and Full-Year 2024 Financial Results - Nasdaq
Skye Bioscience Q4 Earnings: Obesity Treatment Pioneer Reveals 2024 Financial Performance - StockTitan
Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Price Target at $18.67 - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of "Buy" by Analysts - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Trading Down 2%Should You Sell? - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Coverage Initiated at William Blair - MarketBeat
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):